Target intelligence / Profile preview

Coiled-coil-helix-coiled-coil-helix domain-containing protein 6 (CHCHD6)

Target
CHCHD6
Molecular classification
Other, Mitochondrial membrane protein, MICOS complex subunit
01

Overview

Coiled-coil-helix-coiled-coil-helix domain-containing protein 6 (CHCHD6) is a mitochondrial protein predominantly localized to the inner mitochondrial membrane as a core component of the MICOS (mitochondrial contact site and cristae organizing system) complex[1][3][5]. It is essential for the maintenance of cristae morphology and mitochondrial inner membrane architecture, directly interacting with other MICOS proteins like mitofilin and CHCHD3[1][3]. Disruption or loss of CHCHD6 impairs mitochondrial structure, leads to bioenergetic failure, and increases susceptibility to genotoxic stress, thereby reducing cell growth and ATP production[1][2]. In Alzheimer’s disease models and human tissues, CHCHD6 is selectively reduced, linking it to amyloid processing, mitochondrial dysfunction, and neurodegeneration, suggesting a potential therapeutic target for AD and possibly cancer[1][2][5]. It does not belong to classical drug target categories like receptors or enzymes but is considered a target due to its role in disease-related cellular processes.

Other names
MICOS complex subunit MIC25CHCM1MIC25MGC13016PPP1R23Mic25MICOS25coiled-coil-helix cristae morphology protein 1coiled-coil-helix-coiled-coil-helix domain-containing protein 6protein phosphatase 1 regulatory subunit 23coiled-coil-helix cristae morphology 1mitochondrial contact site and cristae organizing system subunit 25
02

Biological functions

Maintenance of mitochondrial cristae morphologyRegulation of mitochondrial inner membrane architectureFormation of mitochondrial contact sitesRegulation of ATP productionOxygen consumptionDNA damage response
03

Disease associations

Neurodegenerative disease (Alzheimer's disease)CancerSpinal muscular atrophy, Jokela type3-methylglutaconic aciduria
04

Safety considerations

Loss or reduction can disrupt mitochondrial bioenergetics and promote neurodegeneration[2]Altered levels may affect cellular sensitivity to DNA damaging chemotherapy[1]
05

Biomarkers

CHCHD6 levels as a biomarker for mitochondrial integrity in neurodegenerative disease (e.g., reduced in Alzheimer’s disease)[2]Potentially predictive for chemosensitivity or resistance in cancers treated with genotoxic agents[1]

Beyond the preview

Go deeper on Coiled-coil-helix-coiled-coil-helix domain-containing protein 6 (CHCHD6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coiled-coil-helix-coiled-coil-helix domain-containing protein 6 (CHCHD6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call